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ABSTRACT
BACKGROUND
Patient-reported symptoms and endoscopic disease activity do not correlate well in 
Crohn’s disease (CD). This warrants the need for reliable biomarkers to early detect ac-
tive intestinal inflammation. Currently, the fecal calprotectin level is the most commonly 
used biomarker for inflammatory activity in CD. However, the diagnostic accuracy of the 
fecal calprotectin level is not fully efficacious and diagnosis may be further improved by 
the identification of other biomarkers for active CD. Here, we studied the association of 
pro-inflammatory serum cytokines with fecal calprotectin levels in CD patients.
METHODS
39 CD patients were included and subdivided into ‘normal’ (defined as < 200 mg/kg 
feces) and ‘increased’ (defined as > 200 mg/kg feces) fecal calprotectin level groups. 
Serum cytokine levels were quantified by an electrochemiluminescence multiplex assay 
(V-PLEX Human Biomarker 40-Plex Kit of Meso Scale Discovery ®). Correlations between 
individual cytokines and the fecal calprotectin level were assessed using Spearman’s 
correlation coefficient (ρ).
RESULTS
A highly significant positive correlation was observed between the pro-inflammatory se-
rum cytokines IFN-γ and CRP and fecal calprotectin levels (P < 0.01). Moreover, fecal 
calprotectin levels showed a significant positive correlation with IL-6, TNF-β, SAA and 
IL-17A (P < 0.05). 
CONCLUSION
We show that a positive correlation exists between multiple serum Th1- and Th17-associ-
ated cytokines and the fecal calprotectin level. These cytokines and CRP may serve as 
additional biomarkers for determining disease activity and evaluating treatment response 
in CD. Ultimately, this may result in more efficient treatment of active disease in CD pa-





Crohn’s disease (CD) is a chronic inflammatory disease that mainly affects the gastro-in-
testinal tract and is characterized by an inappropriate and ongoing immune response. 1 
Most patients suffer from a relapse-remitting disease course that is difficult to predict. 2, 3 
Predicting the disease course is hampered by the poor availability of adequate disease 
biomarkers or symptoms that forecast a flare of inflammation. Longstanding sub-clinical 
disease activity increases the risk of various severe complications, such as stricturing or 
penetrating disease (i.e. fistula or abscess formation). 4 Appropriate and prompt treatment 
of the inflammatory activity lowers the risk of these severe complications, and thus pre-
vents future surgical interventions.
Currently, the only reliable approach for diagnosis of CD is an invasive ileo-colonosco-
py. However, this procedure has several disadvantages, such as the risk of perforati-
on, bleeding, relatively high costs and, most importantly, a high patient burden. Further-
more, a poor association exists between patient-reported symptoms and the observed 
endoscopic inflammatory activity. For instance, clinical risk scores, such as the Harvey 
Bradshaw Index (HBI) or the Crohn’s Disease Activity Index (CDAI), cannot accurately 
predict active intestinal inflammation. 5, 6
In clinical practice, fecal calprotectin levels are commonly used as non-invasive biomar-
ker that significantly correlates with inflammatory disease activity and response to the-
rapy. 5, 7-10 Calprotectin is a 36 kDa calcium- and zinc-binding protein dimer (consisting 
of S100A8 and S100A9) complex present in the cytosol of neutrophilic granulocytes. 11, 
12 Fecal calprotectin levels are representative of neutrophil migration into the intestinal 
mucosa that occurs in the process of intestinal inflammation. Despite its proven associa-
tion with disease activity, the diagnostic accuracy may be further improved by inclusion 
of additional inflammatory biomarkers for active inflammation in CD. 12-14 Many cytokines 
have been shown to be involved in disease pathogenesis and might give a more accurate 
representation of the inflammatory activity in CD relapses in combination with fecal cal-
protectin levels. Ultimately, this may aid in an improved detection of active disease and a 
more versatile and effective treatment. 
A Th1-driven immune response with increased Th1-associated cytokines such as IFN-g 
and TNF-a plays a pivotal role in the pathogenesis of CD. 15 The importance of Th1-res-
ponses is also reflected by the clinical use of TNF-a antagonists, such as infliximab, ada-
limumab and certolizumab, which are effective treatment modalities in CD. 16 Previously, 
quantification of cytokines for diagnosis of disease has been cumbersome due to low 
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serum concentrations of the relevant cytokines, but new techniques enable us to quantify 
most cytokines in a highly sensitive, reproducible and validated manner. 17-19
The aim of this study is to identify potential serum cytokines that might serve as additi-
onal biomarkers for inflammatory disease activity in CD. A positive correlation between 
specific serum cytokines and fecal calprotectin levels might enhance the diagnostic po-






Patients aged 19-67 years with an established diagnosis of Crohn’s disease (CD) were 
included from March 2016 to April 2017 at the University Medical Center Groningen 
(UMCG), the Netherlands. In total, 39 CD patients were included and divided into two 
groups according to inflammatory disease activity, as determined by fecal calprotectin 
levels. Patients having a calprotectin level below 200 mg/kg were defined as the ‘normal’ 
calprotectin group (indicative of remissive disease) and patients with calprotectin levels 
above 200 mg/kg were defined as the ‘increased’ calprotectin group (indicative of inflam-
matory active CD). Clinically relevant data were obtained from medical records: age, ge-
nder, BMI, smoking history, maintenance medication, Montreal score, ileocecal resection 
and laboratory parameters. Fecal calprotectin levels were determined in the laboratory 
of the UMCG as a routine measurement.
CYTOKINE MEASUREMENT
Serum samples from all patients were collected and stored in 1 mL aliquots in the freezer 
(-20°C). After thawing, serum samples were centrifuged for 3 minutes at 2000 g to remo-
ve particulates prior to sample preparation and analysis. Measurement of serum cytokine 
levels was performed by the electrochemiluminescence (ECL) multiplex assay (Meso Sca-
le Discovery (MSD ®), Meso Scale Diagnostics, Rockville, MD). The MSD V-plex Pro-inflam-
matory panel 1 (IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13 and TNF-α), Cytokine 
panel 1 (GM-CSF, IL-5, IL-7, IL-12/23p40, IL-15, IL-16, IL-17A and TNF-β), Chemokine panel 
1 (Eotaxin, MIP-1β, Eotaxin-3, TARC, IP-10, MIP-1α, MCP-1 and MDC), Angiogenesis panel 
1 (VEGF, VEGF-C, VEGF-D, Tie-2, Flt-1, PIGF and bFGF) and Vascular injury panel 1 (SAA, 
CRP, VCAM-1 and ICAM-1) were used to detect a total of 37 cytokines. Calibration curves 
were created in order to calculate serum cytokine concentrations. Calibrator signals were 
fitted to a 4-parameter logistic model with  weighting, providing the assay with a wide 
dynamic range of detection. Cytokine concentrations were calculated by back-fitting ECL 
signals to the calibration curves. Determination of final cytokine concentrations was per-
formed using the MSD Discovery Workbench ® analysis software. Concentrations of all 
cytokines were above the lower limit of detection (LLOD). For the V-plex Pro-inflammatory 
panel 1, Cytokine panel 1 and Angiogenesis panel 1 assays, standard volumes of 50 µL of 
each serum sample were added and diluted 2 times. For the Chemokine panel 1, samples 
were diluted 4 times. For the Vascular injury panel 1, a standard volume of 25 µL of each 
serum sample was added and 1000-fold diluted.
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STATISTICS
Study population characteristics were presented as means ± standard errors (SEM) or 
proportions (%, n). Serum cytokine distributions were presented as median ± interquar-
tile ranges (IQR) and shown in boxplots (10th-90th percentiles) grouped by inflammatory 
disease activity, as determined by the fecal calprotectin level. Correlations between fecal 
calprotectin levels and serum cytokine levels were established using the nonparametric 
Spearman’s correlation coefficient (ρ). Data were analyzed using SPSS Statistics 23.0 






Characteristics of the study population are presented in Table 1. Patients with a ‘normal’ 
fecal calprotectin level (n = 22) had a mean age of 40.5 ± 2.4 years and consisted of 5 
males (22.7%) and 17 females (77.3%). Patients with an increased level of fecal calprotec-
tin (n = 17) had a mean age of 39.7 ± 3.4 years and consisted of 5 males (29.4%) and 12 
females (70.6%). Patients with increased fecal calprotectin levels had significantly higher 
C-reactive protein (CRP) levels (P < 0.01) and higher erythrocyte sedimentation rates (ESR) 
(P < 0.05) as compared to patients with fecal calprotectin levels in the normal range. No 
significant differences between groups were observed for disease location, medication 
use, smoking habits, surgery history and standard laboratory parameters.
TABLE 1: Study population characteristics (n = 39) of Crohn’s disease patients with ‘normal’ (< 200 
mg/kg) and increased (> 200 mg/kg) fecal calprotectin levels.
Characteristics Calprotectin 
< 200 mg/kg (n = 22)
Calprotectin 
> 200 mg/kg (n = 17)
P value
Age (years) 40.5 ± 2.4 39.7 ± 3.4 0.788
Male gender 5 (22,7) 5 (29,4) 0.721
BMI (kg/m2) 24.9 ± 1.4 25.8 ± 1.2 0.350









































Ileocecal resection 8 (36,4) 5 (29,4) 0.740
Hemoglobin (mmol/l) 8.4 ± 0.2 8.4 ± 0.2 0.787
CRP (mg/l) 2.1 ± 0.6 8.2 ± 2.4 *0.002
ESR (mm/h) 12.5 ± 2.2 23.6 ± 4.2 *0.017
WBC (x109/l) 6.9 ± 0.5 6.9 ± 0.4 0.723
Thrombocytes (x109/l) 264 ± 13 308 ± 17 0.229
ASAT (U/l) 22 ± 1 23 ± 3 0.977
ALAT (U/l) 18 ± 2 23 ± 5 0.580
Creatinine (µmol/l) 68 ± 2 70 ± 3 0.681
BMI, body mass index; HBI, Harvey Bradshaw index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; 
WBC, white blood cell count; ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase. Data are pre-
sented as numbers (proportions, n (%)) or mean ± SE. Differences between groups were tested with Mann-Whitney 
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In Table 2, serum cytokine levels (pg/mL) are shown as median values with interquartile 
ranges (IQR) for both groups. Cytokines are grouped in different experimental panels 
(Pro-inflammatory panel, Cytokine panel, Chemokine panel, Angiogenesis panel and Vas-
cular injury panel). 
TABLE 2: Median (IQR) of serum cytokine levels (pg/mL) in Crohn’s disease patients with ‘normal’ (< 
200 mg/kg) and increased (> 200 mg/kg) fecal calprotectin levels.
Cytokines Calprotectin < 200 mg/kg Calprotectin > 200 mg/kg P-value
Pro-inflammatory panel
IFN-γ 7.80 (4.09-19.72) 23.00 (10.13-38.72) < 0.05*
IL-1β 0.05 (0.04-0.08) 0.05 (0.03-0.13) 0.945
IL-2 0.18 (0.12-0.23) 0.17 (0.10-0.25) 0.932
IL-4 0.04 (0.02-0.07) 0.04 (0.03-0.06) 0.777
IL-6 0.78 (0.39-1.15) 1.29 (0.93-1.88) < 0.01**
IL-8 11.91 (7.20-15.43) 12.63 (6.35-68.62) 0.955
IL-10 0.32 (0.19-0.44) 0.37 (0.24-0.74) 0.321
IL-12p70 0.09 (0.03-0.26) 0.07 (0.04-0.18) 0.624
IL-13 0.56 (0.42-0.91) 0.77 (0.55-1.79) 0.153
TNF-α 3.13 (2.50-3.67) 3.49 (2.82-4.79) 0.095
Cytokine panel
GM-CSF 0.16 (0.07-0.29) 0.15 (0.07-0.24) 0.784
IL-5 0.26 (0.16-0.57) 0.26 (0.19-0.54) 0.883
IL-7 19.95 (13.57-28.08) 18.93 (10.18-27.09) 0.552
IL-12/23p40 118.18 (74.94-204.08) 158.38 (125.23-222.36) 0.157
IL-15 3.04 (2.31-5.66) 2.87 (2.44-5.74) 0.777
IL-16 284.06 (203.49-316.63) 285.97 (195.06-327.77) 0.755
IL-17A 5.25 (3.04-9.27) 8.22 (5.11-11.85) 0.058
TNF-β 0.49 (0.34-0.55) 0.55 (0.42-0.66) 0.051
Chemokine panel
Eotaxin 266.32 (179.61-351.18) 240.14 (190.62-356.28) 0.955
MIP-1β 90.12 (73.41-172.00) 80.40 (47.64-129.26) 0.322
Eotaxin-3 20.29 (15.72-30.32) 15.57 (11.79-22.39) 0.101
TARC 242.32 (138.99-512.79) 267.11 (156.86-359.57) 0.799
IP-10 2.99x103 (2.40x103-4.62x103) 3.60x103 (2.25x103-4.66x103) 0.590
MIP-1α 16.27 (13.31-20.75) 16.75 (12.69-24.30) 0.966
MCP-1 217.13 (166.20-357.20) 261.95 (188.06-357.75) 0.630
MDC 1.33x103 (1.02x103-1.69x103) 1.28x103 (1.07x103-1.66x103) 0.977
Angiogenesis panel
VEGF 469.52 (236.89-726.63) 382.16 (223.83-896.71) 0.755
VEGF-C 569.55 (442.96-737.47) 462.11 (375.45-628.34) 0.141
VEGF-D 1.07x103 (770.27-1.47x103) 901.29 (799.81-1.41x103) 0.777
Tie-2 804.11 (652.49-969.74) 708.28 (626.90-845.61) 0.213
Flt-1 147.69 (126.14-167.65) 144.15 (129.16-171.30) 0.932
PIGF 6.28 (5.45-7.40) 5.80 (5.10-7.85) 0.876
bFGF 5.08 (2.05-21.97) 9.12 (2.29-27.11) 0.745
Vascular injury panel





Cytokines Calprotectin < 200 mg/kg Calprotectin > 200 mg/kg P-value
Vascular injury panel
CRP 1.25x106 (6.03x105- 4.67x106) 6.79x106 (3.61x106- 2.64x107) < 0.01**
VCAM-1 8.28x105 (7.83x105-9.64x105) 8.91x105 (7.67x105-1.02x106) 0.671
ICAM-1 4.97x105 (4.27x105-6.00x105) 5.63x105 (4.99x105-7.06x105) 0.062
In the Pro-inflammatory panel, concentrations of IFN-γ and IL-6 were significantly ele-
vated in CD patients with ‘increased’ fecal calprotectin levels as compared to patients 
with ‘normal’ fecal calprotectin levels (IFN-γ: 23.00 pg/mL (IQR: 10.13-38.72) vs.7.80 pg/
mL (IQR: 4.09-19.72)  (P < 0.05); IL-6: 1.29 pg/mL (0.93-1.88) vs. 0.78 pg/mL (0.39-1.15) (P < 
0.01). In addition, in the Vascular injury panel, we found significantly higher concentrations 
of SAA and CRP in patients with increased fecal calprotectin levels as compared to the 
group with normal fecal calprotectin levels (SAA: 9.02x106 pg/mL (IQR: 4.64x106-2.87x107) 
vs. 4.78x106 pg/mL (2.84x106-8.87x106) (P < 0.05); CRP: 6.79x106 pg/mL (IQR: 3.61x106-
2.64x107) vs. 1.25x106 pg/mL (IQR: 6.03x105-4.67x106) (P < 0.01)). In the Cytokine panel, 
Chemokine panel and Angiogenesis panel, no significant differences in serum cytokine 
concentrations were observed between both groups. Interestingly, we also observed 
elevated concentrations of IL-17A and TNF-β in patients with increased fecal calprotectin 
levels, but these were borderline non-significant (P = 0.058 and P = 0.051, respectively).
Distributions of the significantly correlating serum cytokines between groups are shown 
in Figure 1 (IFN-γ and CRP, P < 0.01) and Figure 2 (IL-6, IL-17A, TNF-β and SAA, P < 0.05). 
A highly significant positive correlation was observed between the pro-inflammatory 
cytokines IFN-γ (ρ = 0.523, P < 0.01, Figure 1A) and CRP (ρ = 0.511, P < 0.01, Figure 1B) 
and fecal calprotectin levels. Significant, but less strong correlations were demonstrated 
between IL-6 (ρ = 0.403, P < 0.05, Figure 2A), IL-17A (ρ = 0.352, P < 0.05, Figure 2B), 
TNF-β (ρ = 0.396, P < 0.05, Figure 2C) and SAA (ρ = 0.323, P < 0.05, Figure 2D), and 
fecal calprotectin levels. No significant correlations were observed between the fecal 
calprotectin level and the other 31 investigated cytokines, chemokines and markers for 
angiogenesis and vascular injury.Table 3 provides a complete overview of all (significant 
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FIGURE 1: Distribution of serum cytokine levels in patiens with normal (blue, <200mg/kg) and in-
creased (red, >200mg mg/kg) fecal calprotectin levels, shown in boxplots. A Serum CRP levels (pg/
mL). B Serum IFN-γ levels (pg/mL). *P <0.01.
FIGURE 2: Distribution of serum cytokine levels in patiens with normal (blue, <200mg/kg) and in-
creased (red, >200mg mg/kg) fecal calprotectin levels, shown in boxplots. A Serum IL-6 levels (pg/
mL). B Serum IL-17A levels (pg/mL). C Serum TNF-β levels (pg/mL). D Serum SAA levels (pg/mL). 




TABLE 3: Correlations of fecal calprotectin levels (mg/kg) with serum cytokine levels (pg/mL) in pa-
tients with Crohn’s disease.
Cytokines Spearman’s ρ P-value
Pro-inflammatory panel

















IL-17A 0.352 < 0.05*



















SAA 0.323 < 0.05*
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DISCUSSION
In this study, we show that increased fecal calprotectin levels – a broadly applied marker 
for the assessment of disease activity in CD patients – highly significantly correlates with 
elevated serum IFN-γ and CRP levels. Moreover, significant correlations were observed 
between serum levels of IL-6, IL-17A, TNF-β and SAA and fecal calprotectin levels. These 
findings indicate that identification of cytokine profiles might serve as an additional ap-
proach to determine inflammatory disease activity in CD patients. 
Our data not only provide correlations between fecal calprotectin levels and inflammato-
ry markers in the systemic circulation, but also confirm that Th1 responses are important 
in CD patients with active disease since IFN-γ levels were significantly elevated, as well 
as serum TNF-a levels, although the latter did not reach statistical significance. Further-
more, an interesting additional finding is the borderline non-significant enhancement of 
serum IL-17A levels (P = 0.058) in CD patients with increased fecal calprotectin levels. 
IL-17A has been shown to be a driving effector response for colitis in mice. However, 
transfer of T-cells from IL-17-deficient mice induced severe colitis in mice recipients and 
enhanced IFN-γ-producing T-cells. 20 Likewise, in humans, it is less clear whether IL-17 has 
a protective role or induces an effector response. 21, 22 In our study, we found elevated IL-
17A levels specifically in CD patients with increased fecal calprotectin levels, suggesting 
that it is a marker for inflammatory disease activity instead of a protective marker. Interes-
tingly, we also found that the Th17-stimulating cytokines IL-6 and TNF-β were enhanced 
in the group with increased fecal calprotectin levels, further supporting  that an activated 
Th17 response is involved in these patients in addition to the Th1 response. 
Our findings on the association between C-reactive protein (CRP) and fecal calprotectin 
levels corroborate the findings of other studies. 23, 24 CRP is an acute-phase protein, main-
ly produced by hepatocytes in response to systemic inflammation. Production occurs 
after stimulation by IL-6, IL-1β and TNF-α. In clinical practice, CRP is used as a general 
biomarker for inflammation and is therefore commonly applied to monitor the disease 
course of CD. CRP rapidly increases after an acute-phase stimulus and has a short half-li-
fe, making CRP an useful marker for acute inflammatory events in CD. (25) In CD, active 
disease is significantly associated with both elevated CRP and fecal calprotectin levels. 
14, 26 Elevated CRP levels at diagnosis are predictive for the requirement of future surgical 
interventions in CD and therefore for disease severity. 27 Also, increased CRP levels prior 
to treatment with the TNF-α-antagonist infliximab were predictive of a higher response 
rate and treatment success. 25, 28 Additionally, our data demonstrate that enhanced serum 




the CD patient group with increased fecal calprotectin levels.
In the present study, serum IFN-γ levels were significantly elevated in CD patients with 
increased fecal calprotectin levels, as compared to patients with remissive disease. Like-
wise, it has previously been observed that circulating IFN-γ levels are strongly increased 
in IBD patients as opposed to healthy subjects. 29 IFN-γ is known for its central role in the 
Th1-driven immune response, which constitutes the major signaling pathway in the patho-
genesis of CD. 15 IFN-γ is predominantly produced by Th1-differentiated T-cells residing 
in the intestinal lamina propria upon stimulation by IL-12-producing macrophages in the 
nearby environment. 30 Therefore, since we observe a strong correlation between fecal 
calprotectin levels and serum IFN-γ, this cytokine may be considered as a representative 
marker of endoscopic disease activity driven by Th1-cell cytokine production (IL-6, IL-12, 
TNF-α and IFN-γ). 15, 31 Given these findings, follow-up studies are warranted to determine 
whether therapeutic interference in patients with increased fecal calprotectin levels ac-
companied by high IFN-γ and CRP levels results in improved patient outcomes. 
Finally, we observed a positive correlation between fecal calprotectin levels and serum 
amyloid A (SAA), an acute-phase protein implicated in multiple chronic inflammatory di-
seases and commonly found to be elevated in CD patients. 32 SAA is an apolipoprotein of 
high-density lipoproteins (HDL) and plays a role in cholesterol transport to and from sites 
of inflammation. 33 It has previously been demonstrated that SAA correlates well with 
other acute-phase reactants, such as CRP and alpha-1-antichymotrypsin (alpha-1-ACT) 
and is suggested to be helpful in monitoring CD disease activity. 24, 34
In the present study, the concentrations of a large number of cytokines have been as-
sessed using a highly-sensitive electrochemiluminescence (ECL) assay and were directly 
correlated to the fecal calprotectin level. To our best knowledge, no studies have focused 
on the direct correlations between fecal calprotectin levels and serum cytokine levels 
with such a wide dynamic range of detection, providing us with high sensitivity cytokine 
measurements. However, a limitation of this study is that no endoscopic results were 
obtained in this patient cohort, which is generally considered as gold standard for de-
monstrating disease activity in CD. 35, 36
In conclusion, we show that a positive correlation exist between multiple Th1- and Th17-as-
sociated cytokines and fecal calprotectin level, presenting additional non-invasive can-
didate biomarkers for clinical use in CD patients. Moreover, these candidate cytokine 
biomarkers could be of value in monitoring and treating disease activity in CD. Future 
studies should aim to further assess the diagnostic potential of a distinct cytokine profile 
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in relation to endoscopic activity measures.
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